The results of this work reveal how an alternative splicing mechanism regulates an essential factor for neuronal identity.

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

2018 saw a breakthrough in the field of RNA interference (RNAi), when the US FDA approved the first drug using this gene-silencing mechanism. Five years and five more approved drugs later, RNAi ...

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

We believe the exquisite specificity afforded by the RNAi mechanism of action and our industry-leading, proprietary GalNAc-conjugate approach for delivery to the liver is an unparalleled ...

A team at ORIGINS, a Munich-based Cluster of Excellence, has demonstrated a mechanism that could have enabled the first RNA ...

Rzs and Dz are also being explored as additional mechanisms for gene silencing in many viruses including influenza and have shown their potential in controlling these viruses. Although ...

--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company ... Importantly, based on its unique mechanism of action, Qfitlia has demonstrated efficacy ...